Smartleaf Asset Management LLC Cuts Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Smartleaf Asset Management LLC trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 18.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 752 shares of the company’s stock after selling 171 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Medpace were worth $251,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Centaurus Financial Inc. increased its stake in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after acquiring an additional 29 shares during the last quarter. Schulhoff & Co. Inc. increased its position in Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after purchasing an additional 30 shares during the last quarter. Lindenwold Advisors INC increased its position in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares during the last quarter. Stephens Inc. AR raised its stake in Medpace by 4.9% during the fourth quarter. Stephens Inc. AR now owns 752 shares of the company’s stock valued at $250,000 after purchasing an additional 35 shares in the last quarter. Finally, M&T Bank Corp lifted its position in Medpace by 1.2% during the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock valued at $1,068,000 after purchasing an additional 37 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $381.44.

Medpace Trading Up 1.3 %

MEDP stock opened at $328.56 on Thursday. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a market cap of $10.01 billion, a PE ratio of 26.01, a P/E/G ratio of 3.81 and a beta of 1.36. The company has a 50-day moving average price of $341.61 and a 200 day moving average price of $344.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.